Thyroid Panel Comprehensive

Thyroid stimulating hormone is a 28 kDa glycoprotein gonadotropin secreted by thyrotroph cells of the anterior pituitary in response to hypothalamic thyrotropin-releasing hormone (TRH), and regulated by negative feedback from circulating free thyroid hormones acting at the pituitary and hypothalamic levels. TSH binds the TSH receptor (TSHR) on thyroid follicular cells, stimulating thyroid hormone synthesis and secretion via the adenylyl cyclase-cAMP pathway. TSH exhibits modest diurnal variation — with a nocturnal peak — and is the most sensitive indicator of the set-point relationship between the pituitary and the thyroid gland. Small changes in free thyroid hormone concentration produce logarithmic changes in TSH, making TSH the most amplified and sensitive marker of thyroid-pituitary feedback status.

TSH is the first-line and most sensitive thyroid screening marker across all clinical contexts — primary hypothyroidism, subclinical hypothyroidism, hyperthyroidism, and subclinical hyperthyroidism are all identified first by TSH abnormality before free hormone levels become overtly abnormal. In a comprehensive thyroid panel, TSH serves as the gateway marker that contextualises the free thyroid hormone values — an elevated TSH indicates reduced thyroid hormone output or pituitary resistance; a suppressed TSH indicates excess thyroid hormone or pituitary suppression from exogenous thyroid hormone, thyroid autonomy, or thyrotoxicosis. TSH alone is insufficient for complete thyroid assessment — it does not identify the cause of thyroid dysfunction, does not reflect peripheral thyroid hormone activity, and cannot detect central hypothyroidism.

Free T4 is the unbound, biologically available fraction of thyroxine — approximately 0.02–0.04% of total circulating T4 — and reflects direct thyroid gland secretory output uninfluenced by thyroid binding globulin (TBG), transthyretin, or albumin fluctuations. T4 is the predominant secretory product of the thyroid gland (approximately 80–100 µg/day), functioning primarily as a prohormone that undergoes peripheral deiodination by deiodinase enzymes (DIO1 and DIO2) to the more biologically active triiodothyronine (T3) in liver, kidney, skeletal muscle, and other tissues. Free T4 has a plasma half-life of approximately 7 days.

Free T4 is the standard second-tier thyroid marker, measured alongside TSH to confirm the nature, mechanism, and severity of thyroid dysfunction identified on TSH screening. Elevated Free T4 with suppressed TSH confirms hyperthyroidism; reduced Free T4 with elevated TSH confirms primary hypothyroidism; reduced Free T4 with low or normal TSH confirms central (secondary or tertiary) hypothyroidism where the pituitary is failing to drive thyroid output. In patients on oestrogen therapy — where TBG elevation would artefactually elevate Total T4 — Free T4 provides the clinically reliable measurement of bioavailable thyroxine. In a comprehensive panel, Free T4 is interpreted alongside Free T3 to assess the efficiency of peripheral T4-to-T3 conversion.

Free T3 is the biologically active thyroid hormone that binds nuclear thyroid hormone receptors (TRα and TRβ) and directly mediates the intracellular metabolic effects of thyroid hormone — basal metabolic rate regulation, cardiac chronotropy and inotropy, thermogenesis, protein synthesis, lipid metabolism, and cognitive function. Approximately 80% of circulating T3 is generated by peripheral monodeiodination of T4 by deiodinase enzymes — principally DIO1 and DIO2 — with the thyroid gland directly secreting only approximately 20% of circulating T3. Selenium is a critical cofactor for deiodinase enzymes. Free T3 has a short plasma half-life of approximately 1 day and is approximately three to four times more potent than T4 at nuclear thyroid receptors.

Free T3 is not recommended as a standalone first-line thyroid screening marker by mainstream endocrine guidelines — its value lies in comprehensive thyroid panels where it identifies conditions not detectable by TSH and Free T4 alone. Most critically, impaired T4-to-T3 peripheral conversion — producing normal TSH and normal Free T4 with low-normal Free T3 — represents a clinically significant thyroid hormone insufficiency at the receptor level that is missed entirely by standard two-marker TSH/Free T4 testing. This pattern is common in chronic illness, caloric restriction, selenium deficiency, high-stress states, and is the primary reason comprehensive thyroid panels extend beyond the two-marker standard. Free T3 is also elevated in T3 thyrotoxicosis and T3-predominant Graves' disease, and provides the therapeutic monitoring marker in patients on T3-containing thyroid hormone replacement (desiccated thyroid extract or liothyronine combinations).

Reverse T3 (3,3',5'-triiodothyronine) is a biologically inactive isomer of T3 produced by outer-ring deiodination of T4 by DIO3 — the deiodinase enzyme responsible for inactivating both T4 and T3. rT3 competitively binds thyroid hormone receptors without activating them, acting as a functional antagonist to biologically active T3. Under physiological conditions, approximately 40% of T4 is converted to active T3 (via DIO1/DIO2) and approximately 40% to inactive rT3 (via DIO3), with the remainder undergoing conjugation. The T3:rT3 ratio reflects the balance of activating versus inactivating deiodination pathways. rT3 has a plasma half-life of approximately 4 hours.

rT3 is elevated in non-thyroidal illness syndrome (euthyroid sick syndrome) — where systemic illness, surgery, caloric restriction, chronic stress, and inflammatory states shift deiodination from the T3-producing pathway to the rT3-producing pathway as an energy conservation response. It is also elevated in cortisol excess states, selenium deficiency, heavy metal toxicity, and certain medications. In functional and integrative medicine, elevated rT3 with low-normal Free T3 — despite normal TSH and Free T4 — is interpreted as evidence of impaired T4 activation, with rT3 occupying T3 receptor sites and producing functional thyroid insufficiency despite apparently normal standard thyroid markers. The clinical validity and treatment implications of the rT3:Free T3 ratio as a decision-making tool for T3 supplementation remain debated in mainstream endocrinology. # REVIEWER FLAG: The clinical utility of rT3 measurement as a basis for T3 therapy decisions is contested in mainstream endocrinology and is primarily a functional medicine clinical application — reviewer to confirm appropriate interpretive framing for the platform's practitioner audience.

Total T3 is the combined measurement of protein-bound and free fractions of triiodothyronine in serum. Approximately 99.7% of circulating T3 is bound to TBG, transthyretin, and albumin — only the free fraction is biologically active. Total T3 is therefore significantly influenced by TBG concentration — which is elevated by oestrogens (OCP, HRT, pregnancy) and reduced by androgens, glucocorticoids, and nephrotic syndrome — limiting its utility in populations where TBG levels are altered. Total T3 has historically been used in hyperthyroidism assessment where T3 elevation is diagnostically significant — T3 toxicosis presents with elevated Total T3 and Free T3 alongside suppressed TSH and normal Free T4.

In a comprehensive thyroid panel, Total T3 provides a complementary measure of the full T3 pool alongside Free T3. Its primary clinical utility within the panel is in the assessment of T3 thyrotoxicosis — where T3 is disproportionately elevated relative to T4 — and as a secondary confirmatory marker of T3 status when Free T3 results appear inconsistent with clinical presentation. In routine functional medicine thyroid assessment, Free T3 is the clinically more informative marker as it reflects biologically active T3 independent of binding protein fluctuations; Total T3 adds interpretive value primarily in discordance scenarios.

Thyroid peroxidase (TPO) is the key enzyme responsible for the iodination of thyroglobulin tyrosine residues (organification) and the coupling of iodotyrosines to form T4 and T3 within the thyroid follicular lumen. Anti-TPO antibodies are IgG autoantibodies generated against conformational epitopes on the TPO enzyme, produced by thyroid-infiltrating B-cell plasma cells in the context of autoimmune lymphocytic thyroiditis. They are pathologically active — binding complement and mediating antibody-dependent cellular cytotoxicity (ADCC) against thyroid follicular cells — contributing directly to progressive thyroid gland destruction and the clinical hypothyroidism of established Hashimoto's thyroiditis. Anti-TPO titres tend to decline over the natural history of Hashimoto's disease as the antigen-bearing (functional) thyroid tissue is progressively destroyed.

Anti-TPO is the most sensitive and prevalent autoantibody in autoimmune thyroid disease — present in over 95% of Hashimoto's thyroiditis cases and approximately 75–85% of Graves' disease cases. A positive Anti-TPO in a euthyroid patient indicates the presence of thyroid autoimmunity and confers a significantly elevated risk of progression to clinical hypothyroidism — approximately 2–5% per year with a normal TSH, rising substantially with TSH above 2.5 mIU/L. Anti-TPO positivity in a patient with subclinical hypothyroidism (elevated TSH with normal Free T4) is an indication for levothyroxine therapy per ATA and AACE guidelines when TSH is above 10 mIU/L, and is a stronger argument for treatment when TSH is in the 4.5–10 mIU/L range. In pregnancy, Anti-TPO positivity is associated with increased risk of post-partum thyroiditis, miscarriage, and gestational hypothyroidism.

Thyroglobulin is a large 660 kDa dimeric glycoprotein produced exclusively by thyroid follicular cells, serving as the protein scaffold upon which thyroid hormone synthesis occurs within the follicular colloid. Anti-thyroglobulin antibodies are IgG autoantibodies directed against conformational and linear epitopes on the thyroglobulin molecule, co-occurring with Anti-TPO in many patients with Hashimoto's thyroiditis and Graves' disease. Anti-TG occurs less commonly than Anti-TPO in autoimmune thyroid disease and has lower diagnostic sensitivity alone, but provides additive diagnostic value when Anti-TPO is absent or borderline in a patient with clinical features of autoimmune thyroid disease.

Anti-TG serves two distinct clinical roles within the comprehensive thyroid panel. As an autoimmune thyroid disease marker, Anti-TG is present in approximately 60–80% of Hashimoto's thyroiditis cases and 50–70% of Graves' disease cases — and is diagnostically essential in the minority of patients (approximately 5–10%) who are Anti-TPO-negative but Anti-TG-positive, where Anti-TPO alone would miss the autoimmune diagnosis. As a thyroid cancer monitoring marker, Anti-TG positivity is a critical interpretive confounder in differentiated thyroid cancer (papillary and follicular) surveillance — Anti-TG antibodies interfere with serum thyroglobulin immunoassays, causing falsely low thyroglobulin measurements that underestimate tumour recurrence or residual disease. In thyroid cancer follow-up, Anti-TG positivity must always be documented alongside thyroglobulin levels.

Thyroid stimulating immunoglobulins are a subclass of thyrotropin receptor antibodies (TRAb) that bind and activate the TSH receptor on thyroid follicular cells, mimicking TSH stimulation and driving autonomous thyroid hormone synthesis independent of pituitary feedback regulation. They are IgG autoantibodies generated by B-cell clones in Graves' disease. The TSI bioassay measures functional receptor-stimulating activity; the TRAb competitive immunoassay measures total anti-TSHR antibody including stimulating, blocking, and neutral types. A proportion of TRAb in some patients are thyroid-blocking antibodies (TBAb) — which bind the TSHR but block rather than stimulate — causing hypothyroidism rather than hyperthyroidism. The balance between TSI and TBAb determines clinical thyroid function in TSHR autoantibody-positive patients.

TSI or TRAb is the pathognomonic marker of Graves' disease — the most common cause of hyperthyroidism — and is essential for distinguishing Graves' disease from other causes of hyperthyroidism (toxic multinodular goitre, toxic adenoma, thyroiditis) when the clinical picture is not diagnostic or imaging is unavailable. In a comprehensive thyroid panel, TSI provides the autoimmune hyperthyroidism aetiology marker that complements Anti-TPO and Anti-TG in the autoimmune thyroid disease picture. TSI positivity has critical implications in pregnancy — maternal TSI crosses the placenta and can cause foetal and neonatal Graves' thyrotoxicosis requiring neonatal monitoring. TSI normalisation is also used as a criterion for assessing remission potential before anti-thyroid drug withdrawal in Graves' disease.